secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aditxt, Inc. (ADTX)
CIK:        0001726711
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0001213900-25-060391
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt raises $1M in senior notes, invests $925K in Evofem; CEO targets Evofem close by Sept 2025
--------------------------------------------------------------------------------

- Issued $1M senior notes (10% interest, maturity Sept 30, 2025) at $800K purchase price (20% original issue discount).
- Purchased $1.42M Evofem convertible note and warrant for $925K; convertible at $0.0154/share, warrant exercisable for 5 years.
- Evofem reported ~$20M revenue in 2024; CEO says pending acquisition target close by end of September 2025, subject to shareholder approval.
- Pearsanta near commercialization (end 2025/Q1 2026) for prostate cancer and endometriosis tests using mitochondrial DNA.
- Adimune autoimmune therapeutic platform still early stage; described as 'sleeping giant'; retraining immune system approach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025060391/0001213900-25-060391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025060391/ea0247298-8k_aditxt.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-060391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer